Comparison on serological effect of aerosolized measles vaccine and subcutaneous measles vaccine: a meta-analysis

Abstract

Objective To compare the different seroconversion rates after vaccination of aerosolized measles vaccine (AMV) and subcutaneous measles vaccine (SMV).Methods National Center for Biotechnology Information (NCBI) and Cochrane Library databases were searched to retrieve all randomized controlled trials (RCT) or controlled prospective study (tS) on comparison of serological effect (SE) after vaccination of AMV and SMV.Statistical analysis was performed by RevMan5.1 software.Results Nine studies (6 RCT documents and 3 PS documents) were selected,including 2 349 subjects enrolled in the study (n=1 289 in AMV group,n=1 060 in SMV group).No significant difference was found in seroconversion rate after AMV compared to SMV (OR=0.91,95％ CI:0.36-2.31,P＞0.05).In 6 RCT designs,no statistically difference was noted in seroconversion rate between AMV and SMV (OR=1.32,95％ CI:0.43-4.01,Z=0.49,P＞0.05).The seroconversion rate of AMV was 0.17 times lower than that of SMV among children aged 4-18 months (OR=0.17,95％CI:0.04-0.70,P＜0.01),but 3.45 times higher than that of SMV among children aged 5-14 years (OR=3.45,95％CI:1.62-7.35,P＜0.01).Conclusions The AMV has serological effect as good as SMV,and AMV appears to have more immunogenicity than SMV does in children under the age of 2 years. Key words: Vaccines; Measles; Serological effect; Meta-analysis